This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
On formulation: the licensed product is buffered and includes a preservative in the multi-dose presentation. A reconstituted research preparation matches neither, and stability claims made about the first do not carry over to the second.
Somebody will have a better source than mine, and I hope they post it.
Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
It is worth stating the boring hypothesis before the interesting one.
Narrowing post #30, because the general version has more than one answer.
The practical version of semaglutide formulation is three sentences long. The rigorous version is three pages and reaches the same conclusion with the conditions attached.
The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.
Semaglutide formulation looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.
Post #32 and I disagree about the size of the effect, not about the direction.
Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.
I have kept the units in throughout, for the obvious reason.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Is there a ceiling dose beyond which semaglutide stops adding benefit?
Is there a ceiling dose beyond which semaglutide stops adding benefit? I have a specific reason for asking rather than idle curiosity, and the context is below. Putting the numbers in the first post, because…
|
2 | 14k | 2mo | |
|
Coming back to: Semaglutide in people without diabetes: what the evidence base looks like
On the subject in the title: Semaglutide in people without diabetes: what the evidence base looks like Working notes rather than a conclusion. Two things I would like separated before anyone answers on…
|
+41 | 46 | 1.2k | 4mo |
|
Second pass at: Semaglutide and alcohol: what is actually documented
Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers…
|
+15 | 19 | 4.4k | 13mo |
|
The C-cell question: rodent findings and their human context
Posting this under the heading it deserves: The C-cell question: rodent findings and their human context Everything below is what sits behind that. The question about c-cell question that I actually want…
|
+41 | 45 | 24k | 12mo |
|
Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from
Semaglutide half-life: where the 165 to 184 hour figure comes from Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post, because a question…
|
+112 | 119 | 3.3k | 11mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Albumin binding and how it produces a long half-life
Posting this under the heading it deserves: Second pass at: Albumin binding and how it produces a long half-life Everything below is what sits behind that. A narrow question about Albumin binding,…
|
+7 | 11 | 31k | 17mo |
|
What the published dose-response for semaglutide actually looks like above 2.4 mg
What the published dose-response for semaglutide actually looks like above 2.4 mg — that is the question, and I have not found it answered plainly anywhere I have looked. I would like to know what people here…
|
2 | 10k | 3mo | |
|
The C-cell question: rodent findings and their human context
Posting this under the heading it deserves: The C-cell question: rodent findings and their human context Everything below is what sits behind that. The question about c-cell question that I actually want…
|
+41 | 45 | 24k | 12mo |
|
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile — what changed since
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard…
|
+6 | 10 | 6.1k | 8mo |
|
Cardiovascular risk: reading the outcome trials as a set
Cardiovascular risk: reading the outcome trials as a set Writing it up because I had to work it out twice and would rather nobody else did. Reading back through what has been written here about cardiovascular…
|
4 | 12k | 5mo |